行情

AMGN

AMGN

安进
NASDAQ

实时行情|Nasdaq Last Sale

203.56
+0.35
+0.17%
已收盘, 16:46 10/17 EDT
开盘
201.59
昨收
203.21
最高
204.75
最低
201.52
成交量
139.77万
成交额
--
52周最高
211.90
52周最低
166.30
市值
1,220.75亿
市盈率(TTM)
16.12
分时
5日
1月
3月
1年
5年

分析师评级

24位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AMGN 新闻

  • The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe
  • Benzinga.52分钟前
  • Alexion to Buy Achillion for $930M, Strengthen PNH Franchise
  • Zacks.56分钟前
  • European advisory group backs Amgen and UCB's Evenity
  • Seeking Alpha - Article.1小时前
  • 江淮的逻辑:从未迷失方向 目标一直都在
  • 经济观察报.3小时前

更多

所属板块

制药
+0.54%
制药与医学研究
+0.62%

热门股票

名称
价格
涨跌幅

AMGN 简况

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
展开

Webull提供Amgen, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。